Seres Therapeutics selling global rights to Vowst to Nestle

Seres Therapeutics (MCRB) has agreed to a non-binding memorandum of understanding with Nestle (NSRGY) Health Science in which Nestle Health Science will acquire certain tangible and intangible assets associated with Vowst capsules. This transaction, when completed, supersedes any prior agreements between Nestle and Seres concerning Vowst. Nestle Health Science has been the lead commercialization party for the product since its launch in June 2023 in the U.S. This transaction will allow Nestle Health Science full control over the further development, commercialization, and manufacturing of Vowst in the US and worldwide. Vowst is the first and only FDA-approved orally administered microbiota-based therapeutic to prevent recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent CDI. The transaction is subject to the negotiation of definitive agreements, Seres shareholder approval and other customary conditions.